Double‐Blind Study of Alprazolam, Diazepam, Clonidine, and Placebo in the Alcohol Withdrawal Syndrome: Preliminary Findings
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Both a reduction in the inhibitory effects of GABA (disinhibition) and activation of the sympathetic nervous system are manifested during the alcohol withdrawal syndrome. This study was designed to explore the relative efficacy of medications that differentially affects these two biological systems: the benzodiazepines, which attenuate GABAergic disinhibition, and the α 2‐adrenergic receptor agonists, which decrease sympathetic activation. The benzodiazepine diazepam (n= 6), the α 2‐receptor agonist clonidine (n= 7), the benzodiazepine alprazolam (that is also purported to have α 2‐receptor agonist properties) (n= 6), and placebo (n= 6) were evaluated in their effectiveness in decreasing signs and symptoms of alcohol withdrawal. Drug‐free, alcohol‐dependent patients were administered 1 of the 4 medications in a double‐blind design until symptoms of withdrawal, as measured by the Clinical Instrument Withdrawal Assessment for Alcohol‐Revised, were successfully treated. Alprazolam was significantly more efficacious than both clonidine and placebo in decreasing withdrawal symptoms. Diazepam was more effective than clonidine and placebo on some measures of withdrawal. Clonidine decreased systolic blood pressure significantly more than the other two active drugs and placebo, but was no more effective than placebo in decreasing other symptoms of withdrawal. Alprazolam did not significantly decrease blood pressure compared with diazepam or placebo. Despite the small sample size, these preliminary findings suggest that the efficacy of alprazolam in the treatment of alcohol withdrawal is related to its effect at the benzodiazepine receptor and not its α 2‐receptor agonist properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Cited by
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Benzodiazepines for alcohol withdrawal
Amato, L., Minozzi, S., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005063.pub3 · Cited by 245
REVIEW: Norepinephrine and stimulant addiction
Sofuoglu, M., & Sewell, R. A. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00138.x · Cited by 185
“Journal compilation © 2008 Society for the Study of Addiction Addiction Biology, 14, 119–129 Adinoff 1994; Akhondzadeh et al. 2000).”
BackgroundAlcohol Withdrawal Syndrome: Benzodiazepines and Beyond
Sachdeva, A. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/13407.6538 · Cited by 141
“2015 Sep, Vol-9(9): VE01-VE07 7 [42] Adinoff B.”
BackgroundNoradrenergic targets for the treatment of alcohol use disorder
Haass-Koffler, C. L., Swift, R. M., & Leggio, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4843-6 · Cited by 117
Metadata
- Authors
- Adinoff, B.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 1994-08
- Volume
- 18
- Issue
- 4
- Pages
- 873-878
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2145443131
- Cited by
- 65
- References
- 1
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐Blind Study of Alprazolam, Diazepam, Clonidine, and Placebo in the Alcohol Withdrawal Syndrome: Preliminary Findings. https://app.cochat.ai/papers/10.1111/j.1530-0277.1994.tb00053.x
- The paper
- Adinoff, B. (1994). Double‐Blind Study of Alprazolam, Diazepam, Clonidine, and Placebo in the Alcohol Withdrawal Syndrome: Preliminary Findings. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.1994.tb00053.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.